文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

针对 SARS-CoV-2 NSP12 定向 CD4 T 细胞反应与针对普通感冒冠状病毒的预先存在反应的广泛交叉反应性的证据。

Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4 T-cell response with pre-primed responses directed against common cold coronaviruses.

机构信息

Infectious Diseases Unit I, Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

German Center for Infection Research Deutsches Zentrum für Infektionsforschung (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.

出版信息

Front Immunol. 2023 May 5;14:1182504. doi: 10.3389/fimmu.2023.1182504. eCollection 2023.


DOI:10.3389/fimmu.2023.1182504
PMID:37215095
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10196118/
Abstract

INTRODUCTION: The nonstructural protein 12 (NSP12) of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has a high sequence identity with common cold coronaviruses (CCC). METHODS: Here, we comprehensively assessed the breadth and specificity of the NSP12-specific T-cell response after T-cell expansion with 185 overlapping 15-mer peptides covering the entire SARS-CoV-2 NSP12 at single-peptide resolution in a cohort of 27 coronavirus disease 2019 (COVID-19) patients. Samples of nine uninfected seronegative individuals, as well as five pre-pandemic controls, were also examined to assess potential cross-reactivity with CCCs. RESULTS: Surprisingly, there was a comparable breadth of individual NSP12 peptide-specific CD4 T-cell responses between COVID-19 patients (mean: 12.82 responses; range: 0-25) and seronegative controls including pre-pandemic samples (mean: 12.71 responses; range: 0-21). However, the NSP12-specific T-cell responses detected in acute COVID-19 patients were on average of a higher magnitude. The most frequently detected CD4 T-cell peptide specificities in COVID-19 patients were aa236-250 (37%) and aa246-260 (44%), whereas the peptide specificities aa686-700 (50%) and aa741-755 (36%), were the most frequently detected in seronegative controls. In CCC-specific peptide-expanded T-cell cultures of seronegative individuals, the corresponding SARS-CoV-2 NSP12 peptide specificities also elicited responses . However, the NSP12 peptide-specific CD4 T-cell response repertoire only partially overlapped in patients analyzed longitudinally before and after a SARS-CoV-2 infection. DISCUSSION: The results of the current study indicate the presence of pre-primed, cross-reactive CCC-specific T-cell responses targeting conserved regions of SARS-CoV-2, but they also underline the complexity of the analysis and the limited understanding of the role of the SARS-CoV-2 specific T-cell response and cross-reactivity with the CCCs.

摘要

简介:严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)的非结构蛋白 12(NSP12)与普通感冒冠状病毒(CCC)具有很高的序列同一性。

方法:在这里,我们通过在 27 名 COVID-19 患者中以单个肽分辨率用 185 个重叠的 15 肽全面评估了在 T 细胞扩增后针对 SARS-CoV-2 NSP12 的 NSP12 特异性 T 细胞反应的广度和特异性,这些肽涵盖了 SARS-CoV-2 NSP12 的整个区域。还检查了九名未感染的血清阴性个体以及五名大流行前对照的样本,以评估与 CCC 的潜在交叉反应性。

结果:令人惊讶的是,COVID-19 患者(平均:12.82 种反应;范围:0-25)和血清阴性对照(包括大流行前样本)之间的个体 NSP12 肽特异性 CD4 T 细胞反应的广度相当(平均:12.71 种反应;范围:0-21)。然而,急性 COVID-19 患者中检测到的 NSP12 特异性 T 细胞反应的平均幅度更高。COVID-19 患者中最常检测到的 CD4 T 细胞肽特异性是 aa236-250(37%)和 aa246-260(44%),而在血清阴性对照中最常检测到的肽特异性是 aa686-700(50%)和 aa741-755(36%)。在血清阴性个体的 CCC 特异性肽扩增 T 细胞培养物中,相应的 SARS-CoV-2 NSP12 肽特异性也引起了反应。然而,在 SARS-CoV-2 感染前后进行纵向分析的患者中,NSP12 肽特异性 CD4 T 细胞反应谱仅部分重叠。

讨论:本研究结果表明存在针对 SARS-CoV-2 保守区域的预形成、交叉反应性 CCC 特异性 T 细胞反应,但它们也强调了分析的复杂性以及对 SARS-CoV-2 特异性 T 细胞反应和与 CCC 交叉反应性的作用的有限理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae1/10196118/3637470d64c3/fimmu-14-1182504-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae1/10196118/e50df9246b37/fimmu-14-1182504-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae1/10196118/d32ed8db422b/fimmu-14-1182504-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae1/10196118/9c873e4a26e1/fimmu-14-1182504-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae1/10196118/329c68976ad3/fimmu-14-1182504-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae1/10196118/3637470d64c3/fimmu-14-1182504-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae1/10196118/e50df9246b37/fimmu-14-1182504-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae1/10196118/d32ed8db422b/fimmu-14-1182504-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae1/10196118/9c873e4a26e1/fimmu-14-1182504-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae1/10196118/329c68976ad3/fimmu-14-1182504-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae1/10196118/3637470d64c3/fimmu-14-1182504-g005.jpg

相似文献

[1]
Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4 T-cell response with pre-primed responses directed against common cold coronaviruses.

Front Immunol. 2023

[2]
High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4 and CD8 memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients.

Front Immunol. 2024

[3]
Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.

PLoS Pathog. 2023-7

[4]
SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses.

Front Immunol. 2021

[5]
Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers.

J Infect Dis. 2021-7-2

[6]
Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19.

PLoS Pathog. 2021-9

[7]
Targets and cross-reactivity of human T cell recognition of common cold coronaviruses.

Cell Rep Med. 2023-6-20

[8]
Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic.

Cell Host Microbe. 2022-9-14

[9]
Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.

bioRxiv. 2022-12-1

[10]
Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses.

J Clin Invest. 2021-5-17

引用本文的文献

[1]
Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence.

Sci Transl Med. 2024-6-12

[2]
Human coronavirus OC43-elicited CD4 T cells protect against SARS-CoV-2 in HLA transgenic mice.

Nat Commun. 2024-1-26

[3]
Development and Validation of a Highly Sensitive Multiplex Immunoassay for SARS-CoV-2 Humoral Response Monitorization: A Study of the Antibody Response in COVID-19 Patients with Different Clinical Profiles during the First and Second Waves in Cadiz, Spain.

Microorganisms. 2023-12-16

[4]
Heterotypic responses against nsp12/nsp13 from prior SARS-CoV-2 infection associates with lower subsequent endemic coronavirus incidence.

bioRxiv. 2023-10-24

[5]
Detection of Antibodies against Endemic and SARS-CoV-2 Coronaviruses with Short Peptide Epitopes.

Vaccines (Basel). 2023-8-23

本文引用的文献

[1]
Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.

Cell Rep. 2023-8-29

[2]
Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.

PLoS Pathog. 2023-7

[3]
Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection.

iScience. 2023-6-16

[4]
Computational design of candidate multi-epitope vaccine against SARS-CoV-2 targeting structural (S and N) and non-structural (NSP3 and NSP12) proteins.

J Biomol Struct Dyn. 2023

[5]
SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals.

Viruses. 2022-12-29

[6]
Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity.

J Clin Invest. 2023-1-3

[7]
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.

Nat Rev Immunol. 2023-5

[8]
Anti-Arbovirus Antibodies Cross-React With Severe Acute Respiratory Syndrome Coronavirus 2.

Microbiol Spectr. 2022-12-21

[9]
Structural Homology-Based Drug Repurposing Approach for Targeting NSP12 SARS-CoV-2.

Molecules. 2022-11-10

[10]
UniProt: the Universal Protein Knowledgebase in 2023.

Nucleic Acids Res. 2023-1-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索